Loomis, Sayles & Company
DNA icon

Loomis, Sayles & Company’s Ginkgo Bioworks DNA Stock Holding History

Loomis, Sayles & Company’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-75
Closed -$5K – 773
2023
Q4 		$5K Sell
75
-52
-41% -$3.18K ﹤0.01% 880
2023
Q3 		$9K Buy
127
+68
+115% +$5.44K ﹤0.01% 802
2023
Q2 		$4K Buy
+59
New +$3.49K ﹤0.01% 881

Other funds holding DNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Loomis, Sayles & Company's DNA Position: Q1 2024 in Review

Loomis, Sayles & Company sold out of Ginkgo Bioworks (DNA) in Q1 2024, closing a stake of 75 shares — an estimated $5K sold.

Loomis, Sayles & Company first reported a position in DNA in Q2 2023 and held it in 3 quarters. The position peaked at $9K in Q3 2023. 342 funds tracked by Wall St. Rank hold DNA as of Q1 2024.

  • Loomis, Sayles & Company reported no remaining Ginkgo Bioworks position as of Q1 2024 after selling out during the quarter.
  • Loomis, Sayles & Company sold 75 Ginkgo Bioworks shares in Q1 2024, an estimated $5K.
  • Loomis, Sayles & Company first reported a position in Ginkgo Bioworks in Q2 2023 and held it in 3 quarters.
  • Loomis, Sayles & Company's Ginkgo Bioworks position peaked at $9K in Q3 2023.
  • 342 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q1 2024.

Based on Loomis, Sayles & Company's 13F filing for Q1 2024, filed 14 May 2024.